- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/00 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
Patent holdings for IPC class C07D 239/00
Total number of patents in this class: 176
10-year publication summary
|
9
|
2
|
9
|
10
|
9
|
2
|
4
|
3
|
3
|
4
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme LLC | 3737 |
11 |
| Janssen Pharmaceutica N.V. | 3160 |
3 |
| OliPass Corporation | 35 |
3 |
| Sanofi | 4319 |
3 |
| Merck Sharp & Dohme Corp. | 2183 |
2 |
| Bayer Cropscience AG | 1836 |
2 |
| BASF AG | 121 |
2 |
| Abbvie Inc. | 1799 |
2 |
| ArQule, Inc. | 132 |
2 |
| Dana-Farber Cancer Institute, Inc. | 2666 |
2 |
| Incyte Corporation | 1066 |
2 |
| Lek Pharmaceuticals d.d. | 181 |
2 |
| Novaled AG | 91 |
2 |
| Novaled GmbH | 489 |
2 |
| prAna Biotechnology Limited | 10 |
2 |
| The Salk Institute for Biological Studies | 447 |
2 |
| Sanford Burnham Prebys Medical Discovery Institute | 309 |
2 |
| Vanderbilt University | 2028 |
2 |
| The Board of Regents of the University of Texas System | 2303 |
2 |
| Pharmacosmos A/S | 64 |
2 |
| Other owners | 124 |